#14. Takeda Pharmaceutical
1-1, Doshomachi 4-chome
Chuo-ku, Osaka 540-8645
Japan
Tel: (81) 66 204 2111
Fax: (81) 66 204 2880
www.takeda.com
| Headcount | 14,510 | |
| Year Established | 1781 | |
| Pharma Revenues | $9,019 | +6% |
| Total Revenues | $10,728 | +3% |
| Net Income | $2,2772 | +7% |
| R&D Budget | $1,501 | +14% |
| Drugs Approved/Launched | |
| Drug | Indication |
| atacand/blopress | chronic heart failure |
| rozerem/ramelteon | insomnia |
| amitiza | chronic idiopathic constipation |
| actoplus met | diabetes |
| Drugs Pending Approval | |
| Drug | Indication |
| actos | insulin resistance-improving drug |
| takepron | symptomatic-GERD |
| tmr vaccine | measles and rubella |
| Drugs in Phase IIB and Beyond | |
| Drug | Indication |
| actos | atherosclerosis |
| basen | impaired glucose tolerance |
| tak-475 | hyperlipemia |
| lupron depot | 6-month/prostate cancer |
| tak-242 | severe sepsis |
| tak-428 | diabetic neuropathy |
| tak-654 | diabetes |
| tak-536 | hypertension |
| tak-715 | rheumatoid arthritis |
| tak-128 | diabetic neuropathy |
| syr-322 | diabetes |
| dimesna | chemoprotective agent |
| Top Selling Drugs | |||
| Drug | Indication | Sales | (+/- %) |
| actos | type 2 diabetes | $2,158 | 26% |
| prevacid | peptic ulcers | $1,415 | flat |
| blopress | hypertension | $1,693 | 26% |
| lupron | prostate cancer | $1,083 | 6% |
Account for 67% of total pharma sales, down from 68% in 2004.
PROFILE
With drug revenues of $9.0 billion in fiscal 2005 — the fiscal year for the Japanese companies on our list run from April 1, 2005 to March 31, 2006 — Takeda remains the top Japan-based pharma company, with a pair of merged firms in the #2 and #3 spots: Astellas and Daiichi-Sankyo.
In May 2006, the company unveiled its Management Plan through 2010. Takeda intends to focus on in-house R&D to generate new products and increase its presence in overseas markets. The first target on the plan: $12.4 billion in sales of in-house drugs by 2010, heading toward $17.7 billion in in-house pharma revenues by 2015. R&D will rise to as much as 20% of drug revenues, while earnings per share will increase 7% annually (minus extraordinary events). The company also wants to reach an average market share of 2.5% worldwide in countries in which it has its own sales channels. This translates to maintaining its 7% share in Japan, getting Takeda Pharma North America above 1.5%, passing 1.1% in the six European countries where it sells its own products, and exceeding 1.4% in Asia (not including Japan).
How will Takeda reach these goals? By “focusing on Takeda-ism, which represents the corporate philosophy referring to ‘Integrity = fairness, honesty, perseverance’ as the basis of all the business activities,” according to the company. Part of this strategy involves enhancing what Takeda calls “the MPDRAP function,” which stands for Marketing, Production, Development, Research, Alliances and Patents.
One of the first steps along this new path appears to be the April 2006 decision to end Takeda’s U.S. marketing partnership with Lilly for Actos (diabetes). A Takeda statement remarked that the company “has steadily increased its responsibility for the marketing and sales of Actos throughout the life of the partnership.” Lilly had $189.0 million in Actos revenues in 1Q2006.
In November, the company enhanced its diabetes offerings with the launch of ActoPlus Met, a combination of Actos and metformin that helps patients manage glucose levels. In January, the company’s DDP-4 inhibitor (think Merck’s Januvia and Novartis’ Galvus) entered Phase III. The company gained that product when it acquired Syrrx in March 2005.
In September 2005, Takeda launched insomnia treatment Rozerem in the U.S. On the flipside of that coin, Takeda partnered with Cephalon in June 2005 to promote wakefulness drug Provigil with its 500 U.S.-based CNS salespeople. Cephalon has an option to add Takeda as a partner on pending drug Nuvigil.
Takeda and co-marketer Sucampo (which developed the drug) received FDA approval for Amitiza, a chronic constipation treatment in January 2006 and began marketing the drug in April.
Takeda has big plans for the rest of the decade. We’ll see if Takeda-ism (and a strong R&D focus with good in-licensing) can keep it on target.
